May 23th, 2023 (Shanghai) — We are glad to announce that Dr. Sundeep Lal, the Founder of BioConnexUS Capital, has been invited as a keynote speaker at ACCESS CHINA Boston Forum during June 4th, June 13th-15th. ACCESS CHINA Biotech Forum is the largest corporate access event between Asia and the western biotech industry.
Keynote topic
MedTech ETF analysis and M&A and IPO transactions
About BioConnexUS Capital
Introduction to BioConnexUS Capital*: Your Trusted Advisory Firm in Life Sciences with Cross-Border Deal and Capital Raising Expertise
In the fast-paced and ever-evolving world of life sciences, strategic partnerships and capital raising play a crucial role in driving innovation, growth, and global impact. BioConnexUS Capital is a boutique advisory firm specializing in providing comprehensive and tailored solutions for companies operating in the life sciences sector, with a particular focus on facilitating cross-border deals and capital raising.
With extensive industry knowledge, a vast network of key stakeholders, and a deep understanding of the unique dynamics of the US and global markets, BioConnexUS serves as a trusted partner to guide clients through complex business challenges and opportunities in biotech, medtech, genomics and diagnostics.
At BioConnexUS, we recognize that life sciences companies require more than just financial advice. We combine our expertise in finance, strategy, technology and industry insights to deliver holistic solutions that address the specific needs and goals of each client. Whether it’s navigating regulatory landscapes, identifying strategic partners, or securing funding, our experienced team is dedicated to providing comprehensive advisory services that drive success.
One of BioConnexUS’ core strengths lies in facilitating cross-border deals between the United States and Asia. We understand the intricacies of both markets, including regulatory frameworks, cultural nuances, and business practices. Leveraging our extensive network and cross-functional expertise, we bridge the gap between these two regions, enabling our clients to seize growth opportunities, expand their market reach, and forge strategic alliances.
Additionally, BioConnexUS excels in capital raising, assisting clients in securing funding to fuel their growth and innovation. Our team has a proven track record in connecting life sciences companies with a diverse range of capital sources, including venture capital firms, private equity investors and strategic partners. We guide clients throughout the fundraising process, from developing compelling investment propositions to negotiating favorable terms, ensuring they have the resources they need to thrive.
In summary, BioConnexUS Capital is your trusted partner in the life sciences industry, offering deep expertise cross-border deals and capital raising. With our comprehensive advisory services and deep sector knowledge, we empower companies to navigate complex challenges, unlock growth opportunities, and make a lasting impact in the global life sciences landscape.
*FINRA registered and Broker Dealer Services Provided by BA Securities, LLC, PA.
About the speaker
Dr. Sundeep Lal is a distinguished business development professional with a remarkable track record in the healthcare industry. With extensive deal experience at prestigious organizations such as Merck and Medtronic, Dr. Lal has played a pivotal role in facilitating over $43 billion worth of transformative agreements, ranging from licensing and mergers and acquisitions to cross-border deals, distributor partnerships, and hospital collaborations including Merck’s acquisition of Schering Plough.
Having lived and worked across both the United States and Asia, Dr. Lal brings a unique global perspective to his business endeavors. His deep understanding of the dynamics and intricacies of these diverse markets has enabled him to forge strategic connections and seize opportunities for growth in both regions. Driven by his passion for advancing healthcare and fostering innovation, he has consistently demonstrated a keen ability to identify synergistic partnerships and deliver results.
Dr. Lal is also the founder of BioConnexUS Capital, LLC, a boutique healthcare advisory firm where he has successfully leveraged his extensive network and business acumen to fuel the growth of promising life sciences companies, enabling access of much needed therapies to patients across the world .
With a remarkable blend of deal-making prowess, cross-cultural competence, and entrepreneurial spirit, Dr. Sundeep Lal continues to be a leading thought leader in driving strategic collaborations and catalyzing innovation in the global healthcare arena.
About ACCESS CHINA Boston Forum
“ACCESS CHINA – Boston Forum @BIO” is scheduled to be held on June 4th and June 13th-15th, 2023, in Boston and online, respectively. This event is expected to be the largest Asia-themed gathering during the BIO Convention 2023. The main theme of the forum is “Building Effective Partnerships in Asia: Strategies for Collaboration and Growth”. During the forum, we will cover a range of key topics include drug innovation, market trends, partnership models, and best practices for successful collaborations, etc.
Conference Name: ACCESS CHINA – Boston Forum @BIO
Date & Time: June 4, Sun. (Boston) and June 13-15 (Online)
Content: Keynote Speeches, Panel Discussion, Company Presentations, ChemPartner-ACCESS CHINA Dinner Reception
Scale: Expected 1000 participants Online, 150 participants onsite; 100 company roadshows
Participants: Pharma/Biotech senior management and BDs, investors.
View more information at https://biotochina.org/
关于药通中国-波士顿论坛
“ACCESS CHINA 药通中国-波士顿论坛@BIO”将于2023年6月4-15日在波士顿及线上举行的。此次论坛将是BIO Convention 2023大会期间最大的亚洲主题交流活动。在过去3年时间，药通中国已成功举办13届线上线下活动，帮助近千家公司在药通平台上展出。
大会名称：药通中国-波士顿论坛@BIO
大会日期：2023.6.4（周日，波士顿） 2023.6.13-15（线上）
大会内容：主题演讲、圆桌讨论、海内外优质项目路演、睿智医药-药通中国招待晚宴
大会规模：预计线上1000参会者； 线下150参会者; 100场公司路演
参会观众：海内外医药企业（药企及Biotech）高管及BD、基金高管
查看更多信息： https://biotochina.org/
MORE INFORMATION
Contact US
Register ACCESS CHINA online, please visit: ACCESS CHINA Biotech Forum
For more information, please contact:
Wendi Xiang
Wxiang@yafocapital.com
BioToChina.org 